Literature DB >> 19890985

Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland.

Edward J Newman1, Kieran Breen, Jim Patterson, Donald M Hadley, Katherine A Grosset, Donald G Grosset.   

Abstract

UK-based community studies have found high rates of misdiagnosis in Parkinson's disease (PD). Searches of prescription databases and case records identified 610 patients taking antiparkinson therapy for a PD diagnosis in 92 West of Scotland General Practices. Patients with no documented progression of parkinsonism and/or no increase in antiparkinson medication for 3 years were assessed by two movement disorder specialists. FP-CIT SPECT scanning was performed in clinically uncertain cases. Those considered unlikely to have PD had antiparkinson drugs tapered then stopped, with a minimum of 6 months follow-up. Age, sex and disease duration matched controls were also assessed. 64 of 89 (71.9%) patients meeting selection criteria were assessed, of whom 36 (56.3%) were appropriate for therapy withdrawal. Thirty three of those 36 patients (91.7%) and 3 of 64 (4.7%) controls stopped antiparkinson therapy without deterioration giving an overall total of 36 of 610 (5.9%). The revised diagnoses in this group were mainly essential tremor (ET) (n = 14) and vascular parkinsonism (VP) (n = 10). Patients managed in Primary Care were significantly more likely to complete therapy withdrawal than those attending a specialist clinic (15.3% vs. 2.6%, P < 0.0001). The total annual cost of antiparkinson medication for these 36 patients was 13,400 pounds; the mean duration of diagnosis was 6.8 years (SD 5.6). At least 1 in every 20 patients taking medication for PD is misdiagnosed. Nearly all of these patients can be identified by simple screening of prescription databases and case records in Primary Care, followed by clinical review, which allows withdrawal of unnecessary medication. (c) 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890985     DOI: 10.1002/mds.22829

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Clinical routine use of dopamine transporter imaging in 516 consecutive patients.

Authors:  Claire Thiriez; Emmanuel Itti; Gilles Fénelon; Eva Evangelista; Michel Meignan; Pierre Cesaro; Philippe Remy
Journal:  J Neurol       Date:  2015-02-04       Impact factor: 4.849

2.  What about biomarkers for parkinson's disease?

Authors:  Naga Krishnakanth Madireddy; Dheeraj Kumar Posa; Shivani Naik; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2021-01-01

Review 3.  Artificial intelligence as an emerging technology in the current care of neurological disorders.

Authors:  Urvish K Patel; Arsalan Anwar; Sidra Saleem; Preeti Malik; Bakhtiar Rasul; Karan Patel; Robert Yao; Ashok Seshadri; Mohammed Yousufuddin; Kogulavadanan Arumaithurai
Journal:  J Neurol       Date:  2019-08-26       Impact factor: 4.849

4.  Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders.

Authors:  Graziella Donatelli; Roberto Ceravolo; Daniela Frosini; Michela Tosetti; Ubaldo Bonuccelli; Mirco Cosottini
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-20       Impact factor: 5.081

5.  Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease.

Authors:  M Cosottini; D Frosini; I Pesaresi; G Donatelli; P Cecchi; M Costagli; L Biagi; R Ceravolo; U Bonuccelli; M Tosetti
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-06       Impact factor: 3.825

6.  The correlation between Toxoplasma gondii infection and Parkinson's disease: a case-control study.

Authors:  Mahmoud Mahami Oskouei; Faezeh Hamidi; Mahnaz Talebi; Mehdi Farhoudi; Ali Akbar Taheraghdam; Tohid Kazemi; Homayoun Sadeghi-Bazargani; Esmaeil Fallah
Journal:  J Parasit Dis       Date:  2014-10-14

7.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

8.  Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.

Authors:  Wei Han; Shraddha Sapkota; Richard Camicioli; Roger A Dixon; Liang Li
Journal:  Mov Disord       Date:  2017-09-07       Impact factor: 10.338

9.  Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan.

Authors:  Hsien-Feng Lin; Kuan-Fu Liao; Ching-Mei Chang; Cheng-Li Lin; Shih-Wei Lai
Journal:  Eur J Clin Pharmacol       Date:  2017-10-01       Impact factor: 2.953

10.  Tau acts as an independent genetic risk factor in pathologically proven PD.

Authors:  Gavin Charlesworth; Sonia Gandhi; Jose M Bras; Roger A Barker; David J Burn; Patrick F Chinnery; Stephen M Gentleman; Rita Guerreiro; John Hardy; Janice L Holton; Andrew Lees; Karen Morrison; Una-Marie Sheerin; Nigel Williams; Huw Morris; Tamas Revesz; Nicholas W Wood
Journal:  Neurobiol Aging       Date:  2012-01-04       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.